Dermata Therapeutics, Inc. (DRMA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Dermata Therapeutics reported revenue of $0. Net income was -$7.6M, or -$8.16 per diluted share. Operating activities generated -$7.8M of cash, leaving -$7.8M of free cash flow. At fiscal year end, Dermata Therapeutics held $7.9M in total assets against $1.6M in total liabilities, including $7.5M of cash and equivalents.
Open the full interactive Dermata Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Dermata Therapeutics Key Stats
| Share Price | $0.86 |
|---|---|
| Market Cap | $3.5M |
| 52-Week Range | $0.86 – $4.32 |
| Shares Outstanding | 4.0 million (basic, 2026 Q2) |
Dermata Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$7.9M | -$9.7M | -$8.0M | -$12.5M | -$7.8M |
| Pre-Tax Income | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
| Income Tax | $0 | $0 | $0 | $0 | — |
| Net Income | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
| Diluted EPS | — | — | — | -$80.30 | -$8.16 |
Dermata Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$1.7M | -$1.9M | -$1.8M | -$3.0M |
| Diluted EPS | -$1.65 | -$2.01 | -$0.48 | -$0.74 |
Dermata Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $10.8M | $6.2M | — | — | $7.5M |
| Current Assets | $11.6M | — | — | — | — |
| Total Assets | $11.6M | $6.9M | $8.0M | $3.5M | $7.9M |
| Current Liabilities | $1.5M | — | — | — | — |
| Total Liabilities | $1.5M | $922,634 | $1.6M | $2.0M | $1.6M |
| Shareholders' Equity | $10.1M | $6.0M | $6.4M | $1.6M | $6.2M |
Dermata Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$5.7M | -$8.8M | -$6.4M | -$11.2M | -$7.8M |
| Cash From Financing | $16.0M | $4.3M | $7.6M | $6.9M | $12.1M |
| Free Cash Flow | — | — | — | — | -$7.8M |
Figures from Dermata Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Dermata Therapeutics financials page for every line item.
Dermata Therapeutics Company Profile
| Ticker | DRMA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001853816 |
Frequently Asked Questions
What was Dermata Therapeutics' revenue in fiscal 2025?
Dermata Therapeutics (DRMA) reported revenue of $0 for fiscal 2025.
What is Dermata Therapeutics' annual revenue history?
Dermata Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Dermata Therapeutics' net income in fiscal 2025?
Dermata Therapeutics reported net income of -$7.6M for fiscal 2025.
What was Dermata Therapeutics' earnings per share (EPS) in fiscal 2025?
Dermata Therapeutics' diluted EPS was -$8.16 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Dermata Therapeutics generate in fiscal 2025?
Dermata Therapeutics generated -$7.8M of free cash flow in fiscal 2025.
What was Dermata Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Dermata Therapeutics reported revenue of $0.
How many shares of Dermata Therapeutics are outstanding?
Dermata Therapeutics reported a weighted average of 4.0 million basic shares outstanding in 2026 Q2.
What is Dermata Therapeutics' market cap?
Based on its latest closing price, Dermata Therapeutics (DRMA) has a market capitalization of about $3.5M.
When does Dermata Therapeutics' fiscal year end?
Dermata Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Dermata Therapeutics headquartered?
Dermata Therapeutics lists its business address in San Diego, California in its SEC filings.